HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Breast Cancer Update
00:00
SERENA‑6 and molecular progression debates
Hamilton critiques SERENA‑6 results, quality‑of‑life timing, and whether early ESR1 detection justifies switching therapy.
Play episode from 46:34
Transcript
